Best of FSR Annual Meeting 2020: Immunology Bootcamp – Advances in Targeted Therapies
The hallmarks of immune-mediated inflammatory diseases (IMIDs) result from the intricate interplay of cells, cytokines, and other components of the immune system. Similar pathology underlies related rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, and giant cell arteritis. Understanding the immunopathology of these diseases is essential to understanding the mechanisms of action through which different medications exert their effects. Another emerging trend in rheumatology is the identification and management of immune-related adverse events associated with new cancer immunotherapies; however, providers lack experience in managing these conditions. Biosimilars are another possible new treatment option in IMIDs. In this educational activity, Dr. Vibeke Strand discusses the latest on the pathogenesis and treatments of IMIDs.
Cost: FreeView Offer chevron_right
- 1.25 AMA PRA Category 1 Credit(s)™
- 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program
- The My Healio CME Dashboard keeps track of earned credits and saved activities
- Personalized recommendations make finding your next activity easy
- Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
- FSR Annual Meeting
- Immune-mediated inflammatory diseases (IMIDs)
- Immune system
- Rheumatic diseases
- Rheumatoid arthritis
- psoriatis arthritis
- axial spondyloarthritis
- systemic lumpus erythematosus
- giant cell artetritis
- Cancer immunitherapies
- Immune-related adverse events (irAEs)
Upon successful completion of this educational activity, participants should be better able to:
-Examine common signaling pathways that underlie chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
-Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.
-Communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Additional credit info
This continuing medical education activity is provided by Vindico Medical Education
This activity is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb; and Sanofi Genzyme.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This enduring material is approved for 1 year from the date of original release, October 29, 2020 to October 28, 2021.